Skip to main content
Erschienen in: Advances in Therapy 8/2020

13.06.2020 | Original Research

Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit

verfasst von: Juan A. Riesco, María Hidalgo, David Chipayo, José J. Gómez, Fernando Zaragozá

Erschienen in: Advances in Therapy | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cardiovascular diseases (CVDs) and chronic obstructive pulmonary disease (COPD) have similar prevalence rates and risk factors, and both frequently occur in the same patient. The primary objective of the study was to evaluate the rate of COPD patients among subjects with some form of CVD referring to a smoking cessation unit. The secondary objective was to analyze the demographic and clinical profile of these subjects and to identify independent factors potentially associated with COPD.

Methods

Observational, prospective study involving 132 patients with smoking habits, and some form of CVD, referring to the smoking cessation unit at the Pulmonology Department of the University Hospital of Cáceres, Spain, between October 2015 and March 2017.

Results

A total of 58 patients (43.9%) were diagnosed with COPD. Main CVDs were: ischemic heart disease (76.5%), chronic heart failure (24.8%), peripheral arterial disease (18.5%), and atrial fibrillation (7.6%). Independent factors were: pack-years (> 30 versus < 30; odds ratio, OR 5.3; 95% CI 1.3–21.4); forced expiratory volume in the first second (OR 0.9; 95% CI 0.9–1.0); chronic heart failure (yes versus no; OR 4.7; 95% CI 1.3–16.4); and modified Medical Research Council (mMRC) dyspnea (2–3 versus 0; OR 18.7; 95% CI 1.9–182.0).

Conclusions

Four of ten patients with some form of CVD also experience COPD. Dyspnea, airflow limitation, smoking habits, and chronic heart failure were significant factors associated with COPD in patients with CVD. Smoking cessation units are useful to improve the diagnosis of COPD in these patients. Further prospective studies with a greater cohort of patients are required to corroborate the present results and to enhance the knowledge of the clinical profile of these patients.
Literatur
2.
Zurück zum Zitat Blanco I, Diego I, Bueno P, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. Int J Chronic Obstr Pulm Dis. 2017;13:57–67.CrossRef Blanco I, Diego I, Bueno P, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. Int J Chronic Obstr Pulm Dis. 2017;13:57–67.CrossRef
3.
Zurück zum Zitat Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148(4):971–85.PubMedCrossRef Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148(4):971–85.PubMedCrossRef
4.
Zurück zum Zitat Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest. 2013;144(6):1811–8.PubMedCrossRef Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest. 2013;144(6):1811–8.PubMedCrossRef
5.
Zurück zum Zitat Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–49.PubMedCrossRef Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–49.PubMedCrossRef
6.
Zurück zum Zitat Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3):1602265.PubMedCrossRef Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3):1602265.PubMedCrossRef
7.
Zurück zum Zitat Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.PubMedCrossRef Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.PubMedCrossRef
8.
Zurück zum Zitat Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.PubMedCrossRef Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.PubMedCrossRef
9.
Zurück zum Zitat Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseases. J Comorbidity. 2013;3:4–9.CrossRef Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseases. J Comorbidity. 2013;3:4–9.CrossRef
10.
Zurück zum Zitat Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–433.PubMedCrossRef Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–433.PubMedCrossRef
12.
Zurück zum Zitat van Oostrom SH, Picavet HS, de Bruin SR, et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam Pract. 2014;15:61.PubMedPubMedCentralCrossRef van Oostrom SH, Picavet HS, de Bruin SR, et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam Pract. 2014;15:61.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Wong MC, Liu J, Zhou S, et al. The association between multimorbidity and poor adherence with cardiovascular medications. Int J Cardiol. 2014;177:477–82.PubMedCrossRef Wong MC, Liu J, Zhou S, et al. The association between multimorbidity and poor adherence with cardiovascular medications. Int J Cardiol. 2014;177:477–82.PubMedCrossRef
14.
Zurück zum Zitat Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.PubMedCrossRef Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.PubMedCrossRef
15.
Zurück zum Zitat Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430–9.PubMedCrossRef Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430–9.PubMedCrossRef
16.
Zurück zum Zitat Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2016;67:130–8.PubMedCrossRef Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2016;67:130–8.PubMedCrossRef
17.
Zurück zum Zitat McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–5.PubMedPubMedCentralCrossRef McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–5.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.PubMedPubMedCentralCrossRef Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–36.PubMedCrossRef Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–36.PubMedCrossRef
20.
Zurück zum Zitat Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6.PubMedPubMedCentralCrossRef Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Miravitllesa M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–35. Miravitllesa M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–35.
22.
Zurück zum Zitat Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057.PubMedCrossRef Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057.PubMedCrossRef
23.
Zurück zum Zitat Montserrat-Capdevila J, Seminario MA, Godoy P, et al. Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. Med Clin. 2018;151(10):383–9.CrossRef Montserrat-Capdevila J, Seminario MA, Godoy P, et al. Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. Med Clin. 2018;151(10):383–9.CrossRef
24.
Zurück zum Zitat Anzueto A, Miravitlles M. Pathophysiology of dyspnea in COPD. Postgrad Med. 2017;129(3):366–74.PubMedCrossRef Anzueto A, Miravitlles M. Pathophysiology of dyspnea in COPD. Postgrad Med. 2017;129(3):366–74.PubMedCrossRef
25.
Zurück zum Zitat Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136:1473–9.PubMedPubMedCentralCrossRef Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136:1473–9.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Miravitlles M, de la Roza C, Morera J, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med. 2006;100(11):1973–80.PubMedCrossRef Miravitlles M, de la Roza C, Morera J, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med. 2006;100(11):1973–80.PubMedCrossRef
27.
Zurück zum Zitat Engström G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers-an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000;7(4):267–72.PubMedCrossRef Engström G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers-an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000;7(4):267–72.PubMedCrossRef
28.
Zurück zum Zitat Franssen FM, Soriano JB, Roche N, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016;194(5):568–76.PubMedCrossRef Franssen FM, Soriano JB, Roche N, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016;194(5):568–76.PubMedCrossRef
29.
Zurück zum Zitat Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012;14(4):414–22.PubMedPubMedCentralCrossRef Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012;14(4):414–22.PubMedPubMedCentralCrossRef
Metadaten
Titel
Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit
verfasst von
Juan A. Riesco
María Hidalgo
David Chipayo
José J. Gómez
Fernando Zaragozá
Publikationsdatum
13.06.2020
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 8/2020
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01403-0

Weitere Artikel der Ausgabe 8/2020

Advances in Therapy 8/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.